Alzamend Neuro, Inc. (NASDAQ:ALZN) Financings
Financings
| Raise | Date |
|---|---|
| Series D Convertible Preferred Stock Tranche closed: US$7.5M raised · US$1,000 a share Buyers: Ault Lending, LLC (agreed to purchase up to 25,000 Preferred Shares for $25,000,000; purchased 7,500 Preferred Shares for $7,500,000 at the initial closing) Use of proceeds: General working capital and corporate purposes, including furthering its clinical trials | Aug 4, 2026 |
| Private placement of series C Convertible Preferred Stock and warrants Closed: private placement Use of proceeds: To support the five Phase II clinical trials of AL001 Lithium in Brain studies at Massachusetts General Hospital | Jun 16, 2025 |